Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Peking promotes the large-scale deployment of 10,000 embodied Siasun Robot&Automation, with policy support accelerating industry development.

The "Peking Embodied Asia Vets Technology Innovation and Industry Cultivation Action Plan (2025-2027)" was officially released in Peking. The "Action Plan" states that by 2027, efforts will aim to implement the large-scale deployment of ten thousand embodied Siasun Robot&Automation units and cultivate a trillion-level industrial cluster.

cls.cnMar 2 18:58 ET

Building a high-frequency communication platform, the "Shanghai Lujiazui Finance & Trade Zone Development Salon" is about to launch with exciting events happening weekly.

① In response to the Shanghai Lujiazui Finance & Trade Zone Development Forum, build an integrated ecosystem of "Global Strategy - Execution." ② The first event on March 1 will focus on "Opportunities and Challenges: Great Power Game, Exchange Rates, and the Construction of the Shanghai International Financial Center."

cls.cnFeb 25 21:24 ET

The final ruling has changed! Innovative Medical Management has revised its 2024 performance forecast, with the company accumulating losses of nearly 1.8 billion over six years | Interpretations

① Only a month after the performance forecast for 2024 was disclosed, Innovative Medical Management has revised its performance forecast, with net losses expanding to 0.1 billion yuan - -85 million yuan; ② Innovative Medical Management had made relevant risk warnings in its performance forecast, and the dispute case between Qianhai Excellence and Jianhua Hospital has been heard but not yet ruled; ③ Since 2019, Innovative Medical Management has reported losses for six consecutive years, with a cumulative loss amounting to nearly 1.8 billion yuan.

cls.cnFeb 25 09:10 ET

The delay in hospital bidding combined with an increase in research and development costs has led to a decline of over fifty percent in Xiangyu Medical's net profit in 2024.

① Xiangyu Medical expects that by 2025 all expenses can be stably controlled, and the company's Net income will return to a growth trend. Mental health products have already met the marketable conditions outside hospitals, and proactive training products are expected to obtain registration certificates by 2025; ② In January 2025, Xiangyu Medical added two new training products that received CE certification, and it is expected that two therapeutic products will obtain certification by mid-2025.

cls.cnFeb 21 09:23 ET

The Robot Concept is experiencing explosive growth! The strongest stock has risen nearly 7 times, and these stocks have all reached new historical highs.

YuTree Technology's Wang Xingxing recently stated that by the end of this year, the entire humanoid robot in the field of AI will reach a new level.

cls.cnFeb 19 01:30 ET